Key result
Deutaleglitazar improves diabetic dyslipidemia and hyperglycemia with reversible eGFR reduction and dose-related neutropenia.
Why the study?
Deutaleglitazar is a novel dual PPAR alpha and gamma agonist with potential combined benefits in diabetic kidney disease management, but its pharmacokinetics, pharmacodynamics, safety, and tolerability required evaluation.
Does deutaleglitazar demonstrate favorable pharmacokinetics, pharmacodynamics, and safety in healthy participants and patients with diabetic kidney disease?
RCT (n=98)
randomized
No
Does deutaleglitazar demonstrate favorable pharmacokinetics, pharmacodynamics, and safety in healthy participants and patients with diabetic kidney disease?
Answers are grounded in this paper and cite their sources.
Deutaleglitazar, a novel dual PPAR α/γ agonist, demonstrates predictable pharmacokinetics and favorable metabolic effects in early-phase trials, though it is associated with reversible eGFR declines and dose-dependent neutropenia.
Introduction Deutaleglitazar (AP303) is a novel dual peroxisome proliferator-activated receptor (PPAR) α and γ agonist, which has the potential to offer the combined clinical benefit on diabetic kidney disease (DKD) management by normalizing the elevated glomerular capillary pressure, ameliorating podocyte depletion, as well as correcting diabetic dyslipidemia and hyperglycemia Methods Three single-center, randomized, placebo-controlled single-ascending-dose and/or multiple-ascending-dose studies investigated its pharmacokinetics (PK), pharmacodynamic, safety and tolerability in healthy participants with different ethnicities and in patients with diabetic kidney disease (DKD) and reduced kidney function. Results A total of 80 healthy participants, and 18 patients with DKD and estimated glomerular filtration rate (eGFR) 30-60 mL/min/1.73m 2 from Australia and China received either placebo, a single oral dose or multi-dose of deutaleglitazar for 14 days. Deutaleglitazar exposure increased in a dose-dependent manner both after a single dose and at steady state, with no accumulation. Minor differences of PK profiles in Caucasian vs. Asian participants, and in those with normal vs reduced kidney function are considered unlikely to be clinically significant. Reduction in eGFR with reversibility after drug discontinuation was evident. Improvement in diabetic dyslipidemia and hyperglycemia were observed. Few adverse events were reported, only neutropenia was dose related. Conclusion The PPARα and PPARγ related effects occurred over similar dose ranges, indicating that deutaleglitazar is a balanced agonist of the two receptor subtypes targeting on the root cause and multi-pathway of DKD progression.
No takes yet. Share an insight, caveat, or question.
Perkovic et al. (2026) conducted an RCT in Diabetic kidney disease (n=98). Deutaleglitazar vs. placebo was evaluated on pharmacokinetics, pharmacodynamics, safety and tolerability. Deutaleglitazar showed dose-dependent exposure, reversible eGFR reduction, and improved diabetic dyslipidemia and hyperglycemia, with neutropenia as the only dose-related adverse event.
Synapse has enriched 10 related papers. Consider them for comparative context: